Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How Brazilian drugmaker Blau Farmacêutica quietly built a pembrolizumab biosimilar that could challenge Big Pharma
Blau Farmacêutica completes Brazil’s first full pembrolizumab biosimilar. Find out how this could reshape global immunotherapy access and biosimilar strategy. Read More
U.S. Department of Veterans Affairs awards EsoGuard contract to Lucid Diagnostics
Explore how Lucid Diagnostics’ VA contract validates EsoGuard, shaping investor sentiment, competitive positioning, and nationwide adoption of non-invasive cancer diagnostics. Read More
Will Sarepta’s Elevidys succeed where others stalled? All eyes on EMBARK trial’s 3-year data drop
Find out how Sarepta’s 3-year Elevidys trial data could reshape investor sentiment, regulatory outlook, and Duchenne gene therapy strategy. Read More
Ateganosine Phase 3 marks inflection point for MAIA Biotechnology with 2026 milestones in focus
Find out how MAIA Biotechnology’s Phase 3 ateganosine trial and 2026 milestones could reshape its regulatory path and investor narrative. Read More
From lab validation to clinical execution: Adaptin Bio advances a novel glioblastoma therapy toward trials
Find out how Adaptin Bio is moving a novel glioblastoma therapy from lab validation into early clinical execution and what this step means for brain ... Read More
Insilico Medicine, Hygtia Therapeutics to advance AI-designed NLRP3 inhibitor for CNS diseases
Insilico and Hygtia partner to advance ISM8969, a brain-penetrant AI-designed NLRP3 inhibitor for CNS diseases. Find out what this means for the field. Read More
Avacta Therapeutics (AIM: AVCT) secures FDA clearance for AVA6103 as pre|CISION platform enters its second clinical test
Avacta Therapeutics secures FDA IND clearance for AVA6103, advancing its pre|CISION platform into a second clinical program. Read what changes next. Read More
Eli Lilly’s sofetabart mipitecan earns FDA Breakthrough Therapy status in platinum-resistant ovarian cancer
Eli Lilly's sofetabart mipitecan receives FDA Breakthrough Therapy designation in platinum-resistant ovarian cancer. Find out what this means for the ADC space. Read More
GSK to acquire RAPT Therapeutics in strategic push into long-acting food allergy biologics
GSK to acquire RAPT Therapeutics for $2.2B, targeting food allergy breakthroughs with ozureprubart. Find out how this changes its immunology strategy. Read More
Why Celcuity’s FDA priority review for gedatolisib could reset the breast cancer playbook
Celcuity earns FDA priority review for gedatolisib in advanced breast cancer. Find out what the July 2026 PDUFA date means for its market trajectory. Read More